NYSE:AZN - AstraZeneca Stock Price, Price Target & More

$35.34 -0.06 (-0.17 %)
(As of 04/20/2018 04:00 PM ET)
Previous Close$35.34
Today's Range$35.28 - $35.50
52-Week Range$28.43 - $36.75
Volume2.49 million shs
Average Volume4.18 million shs
Market Capitalization$89.66 billion
P/E Ratio8.26
Dividend Yield3.87%
Beta0.62

About AstraZeneca (NYSE:AZN)

AstraZeneca logoAstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases. The company's marketed products also comprise Accolate, Bevespi Aerosphere, Bricanyl Respules, Bricanyl Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Eklira Genuair/Tudorza Pressair, Fasenra, Oxis Turbuhaler, Pulmicort Turbuhaler/Pulmicort Flexhaler, Pulmicort Respules, Symbicort pMDI, Symbicort Turbuhaler, and Tudorza Pressair for respiratory diseases; Fluenz FluMist/Tetra Quadrivalen and Synagis3 for infection diseases; Movantik/Moventig, Seroquel IR, Seroquel XR, and Vimovo4 for neuroscience diseases; and Losec/Prilosec and Nexium for gastrointestinal diseases. AstraZeneca PLC serves primary care and specialty care physicians through distributors and local representative offices. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was founded in 1992 and is headquartered in Cambridge, the United Kingdom.

Receive AZN News and Ratings via Email

Sign-up to receive the latest news and ratings for AZN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNYSE:AZN
CUSIPN/A
Phone44-0-20-3749-5000

Debt

Debt-to-Equity Ratio0.93%
Current Ratio0.80%
Quick Ratio0.62%

Price-To-Earnings

Trailing P/E Ratio8.26
Forward P/E Ratio20.79
P/E Growth1.88

Sales & Book Value

Annual Sales$22.47 billion
Price / Sales3.98
Cash Flow$3.3340 per share
Price / Cash10.60
Book Value$6.57 per share
Price / Book5.38

Profitability

EPS (Most Recent Fiscal Year)$4.28
Net Income$3.00 billion
Net Margins13.36%
Return on Equity34.74%
Return on Assets8.52%

Miscellaneous

Employees59,700
Outstanding Shares2,532,900,000

How to Become a New Pot Stock Millionaire

AstraZeneca (NYSE:AZN) Frequently Asked Questions

What is AstraZeneca's stock symbol?

AstraZeneca trades on the New York Stock Exchange (NYSE) under the ticker symbol "AZN."

How often does AstraZeneca pay dividends? What is the dividend yield for AstraZeneca?

AstraZeneca declared a semiannual dividend on Monday, February 5th. Investors of record on Friday, February 16th will be paid a dividend of $0.95 per share on Monday, March 19th. This represents a yield of 5.62%. The ex-dividend date of this dividend is Thursday, February 15th. View AstraZeneca's Dividend History.

When did AstraZeneca's stock split? How did AstraZeneca's stock split work?

AstraZeneca shares split on the morning of Monday, July 27th 2015. The 2-1 split was announced on Friday, June 26th 2015. The newly created shares were payable to shareholders after the closing bell on Friday, July 24th 2015. An investor that had 100 shares of AstraZeneca stock prior to the split would have 200 shares after the split.

How were AstraZeneca's earnings last quarter?

AstraZeneca (NYSE:AZN) issued its quarterly earnings results on Friday, February, 2nd. The company reported $1.30 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.44 by $0.86. The business earned $5.78 billion during the quarter, compared to analyst estimates of $5.49 billion. AstraZeneca had a net margin of 13.36% and a return on equity of 34.74%. The company's quarterly revenue was up 3.4% on a year-over-year basis. During the same period last year, the company posted $1.21 earnings per share. View AstraZeneca's Earnings History.

When is AstraZeneca's next earnings date?

AstraZeneca is scheduled to release their next quarterly earnings announcement on Friday, May, 18th 2018. View Earnings Estimates for AstraZeneca.

What guidance has AstraZeneca issued on next quarter's earnings?

AstraZeneca updated its FY18 earnings guidance on Friday, February, 2nd. The company provided earnings per share guidance of $3.30-3.50 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $3.64.

What price target have analysts set for AZN?

18 analysts have issued 1 year target prices for AstraZeneca's stock. Their forecasts range from $35.00 to $42.00. On average, they expect AstraZeneca's share price to reach $38.1167 in the next twelve months. View Analyst Ratings for AstraZeneca.

Who are some of AstraZeneca's key competitors?

Who are AstraZeneca's key executives?

AstraZeneca's management team includes the folowing people:
  • Mr. Pascal Soriot, Exec. Director & CEO (Age 59)
  • Mr. Marc Dunoyer, Exec. Director & CFO (Age 66)
  • Ms. Pam P. Cheng, Exec. Vice-Pres of Operations & Information Technology (Age 47)
  • Mr. Jefrey Pott, Gen. Counsel
  • Ms. Katarina Ageborg, Exec. VP of Sustainability & Chief Compliance Officer

Has AstraZeneca been receiving favorable news coverage?

Media headlines about AZN stock have been trending somewhat positive this week, Accern reports. Accern identifies positive and negative news coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. AstraZeneca earned a news impact score of 0.11 on Accern's scale. They also assigned media headlines about the company an impact score of 45.09 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.

How do I buy shares of AstraZeneca?

Shares of AZN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is AstraZeneca's stock price today?

One share of AZN stock can currently be purchased for approximately $35.34.

How big of a company is AstraZeneca?

AstraZeneca has a market capitalization of $89.66 billion and generates $22.47 billion in revenue each year. The company earns $3.00 billion in net income (profit) each year or $4.28 on an earnings per share basis. AstraZeneca employs 59,700 workers across the globe.

How can I contact AstraZeneca?

AstraZeneca's mailing address is 1 Francis Crick Avenue Cambridge Biomedical Campus, Cambridge X0, CB2 0AA. The company can be reached via phone at 44-0-20-3749-5000 or via email at [email protected]


MarketBeat Community Rating for AstraZeneca (AZN)

Community Ranking:  1.8 out of 5 (star)
Outperform Votes:  516 (Vote Outperform)
Underperform Votes:  890 (Vote Underperform)
Total Votes:  1,406
MarketBeat's community ratings are surveys of what our community members think about AstraZeneca and other stocks. Vote "Outperform" if you believe AZN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AZN will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

AstraZeneca (NYSE:AZN) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
18 Wall Street analysts have issued ratings and price targets for AstraZeneca in the last 12 months. Their average twelve-month price target is $38.1167, suggesting that the stock has a possible upside of 7.86%. The high price target for AZN is $42.00 and the low price target for AZN is $35.00. There are currently 1 sell rating, 5 hold ratings and 12 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.612.582.552.52
Ratings Breakdown: 1 Sell Rating(s)
5 Hold Rating(s)
12 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
6 Hold Rating(s)
12 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
7 Hold Rating(s)
12 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
10 Hold Rating(s)
14 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $38.1167$36.3214$35.0917$35.7029
Price Target Upside: 7.86% upside4.82% upside0.06% upside3.13% upside

AstraZeneca (NYSE:AZN) Consensus Price Target History

Price Target History for AstraZeneca (NYSE:AZN)

AstraZeneca (NYSE:AZN) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/22/2018BMO Capital MarketsSet Price TargetBuy$40.00LowView Rating Details
3/19/2018Jefferies GroupUpgradeHold -> Buy$28.43 -> $36.70LowView Rating Details
2/6/2018Leerink SwannBoost Price TargetMarket Perform -> Market Perform$36.00 -> $38.00MediumView Rating Details
2/5/2018Sanford C. BernsteinBoost Price TargetOutperform$40.00 -> $42.00HighView Rating Details
12/29/2017JPMorgan ChaseUpgradeNeutral -> OverweightLowView Rating Details
10/18/2017CitigroupUpgradeBuyN/AView Rating Details
10/17/2017CowenReiterated RatingHold$37.00N/AView Rating Details
10/16/2017Credit Suisse GroupUpgradeNeutral -> OutperformN/AView Rating Details
9/25/2017BNP ParibasUpgradeNeutral -> OutperformMediumView Rating Details
9/14/2017Liberum CapitalDowngradeBuy -> HoldLowView Rating Details
9/6/2017NatixisUpgradeNeutral -> BuyLowView Rating Details
9/1/2017ArgusReiterated RatingBuy$35.00LowView Rating Details
8/9/2017InvestecUpgradeHold -> BuyLowView Rating Details
8/9/2017Piper JaffrayReiterated RatingBuyLowView Rating Details
8/1/2017Pareto SecuritiesUpgradeSell -> HoldLowView Rating Details
7/28/2017Morgan StanleyDowngradeOverweight -> Equal WeightHighView Rating Details
7/13/2017Goldman SachsReiterated RatingSellHighView Rating Details
7/13/2017BarclaysReiterated RatingOverweightHighView Rating Details
4/5/2017UBSDowngradeBuy -> Neutral$35.44 -> $25.55N/AView Rating Details
2/21/2017Berenberg BankReiterated RatingBuyN/AView Rating Details
11/11/2016Deutsche BankReiterated RatingBuyN/AView Rating Details
11/11/2016Beaufort SecuritiesReiterated RatingHoldN/AView Rating Details
11/10/2016Cantor FitzgeraldReiterated RatingBuyN/AView Rating Details
11/10/2016Bank of AmericaReiterated RatingBuy$41.37N/AView Rating Details
11/10/2016Shore CapitalReiterated RatingHoldN/AView Rating Details
(Data available from 4/21/2016 forward)

Earnings

AstraZeneca (NYSE:AZN) Earnings History and Estimates Chart

Earnings by Quarter for AstraZeneca (NYSE:AZN)

AstraZeneca (NYSE:AZN) Earnings Estimates

2018 EPS Consensus Estimate: $1.67
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181$0.42$0.42$0.42
Q2 20181$0.40$0.40$0.40
Q3 20181$0.39$0.39$0.39
Q4 20181$0.46$0.46$0.46

AstraZeneca (NYSE AZN) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/18/2018$0.28N/AView Earnings Details
2/2/2018Q4 2017$0.44$1.30$5.4936 billion$5.7770 billionViewListenView Earnings Details
11/9/2017Q3$0.57$1.12$5.9999 billion$6.2320 billionViewN/AView Earnings Details
7/27/20176/30/2017$0.41$0.87$5.0391 billion$5.0510 billionViewN/AView Earnings Details
4/27/20173/31/2017$0.38$0.99$5.4045 billion$5.4050 billionViewN/AView Earnings Details
2/2/2017Q416$0.51$1.21$5.43 billion$5.5850 billionViewListenView Earnings Details
11/10/2016Q316$0.48$1.32$5.95 billion$5.6990 billionViewN/AView Earnings Details
7/28/2016Q216$0.76$0.83$5.56 billion$5.60 billionViewListenView Earnings Details
4/29/2016Q1$0.5970$0.51$5.96 billion$6.12 billionViewListenView Earnings Details
2/4/2016Q415$0.88$0.94$6.27 billion$6.40 billionViewN/AView Earnings Details
11/5/2015Q315$0.51$1.03$5.90 billion$5.85 billionViewN/AView Earnings Details
7/30/2015Q2$0.52$1.21$6.0159 billion$5.8360 billionViewListenView Earnings Details
4/24/2015Q1$1.07$1.08$5.8724 billion$6.0570 billionViewN/AView Earnings Details
2/5/2015Q314$0.85$0.76$6.68 billion$6.6830 billionViewN/AView Earnings Details
11/6/2014Q3$1.04$1.05$6.4398 billion$6.5420 billionViewN/AView Earnings Details
7/31/2014Q214$1.09$1.30$6.24 billion$6.4540 billionViewN/AView Earnings Details
4/29/2014Q114$1.23$1.17$6.32 billion$6.42 billionViewN/AView Earnings Details
2/6/2014Q413$1.22$1.23$6.91 billion$3.84 billionViewN/AView Earnings Details
10/31/2013Q313$1.27$1.21$6.45 billion$6.25 billionViewN/AView Earnings Details
8/1/2013Q213$1.16$1.20$6.24 billion$6.23 billionViewN/AView Earnings Details
4/25/2013$1.36$1.41$6.5431 billion$6.3850 billionViewN/AView Earnings Details
1/31/2013Q412$1.37$1.56$7.17 billion$7.2820 billionViewN/AView Earnings Details
10/25/2012$1.44$1.51ViewN/AView Earnings Details
7/26/2012$1.38$1.53ViewN/AView Earnings Details
4/26/2012$1.73$1.81ViewN/AView Earnings Details
2/2/2012$1.57$1.61ViewN/AView Earnings Details
10/27/2011$1.64$1.71ViewN/AView Earnings Details
7/28/2011$1.74$1.53ViewN/AView Earnings Details
4/27/2011Q1 2011$1.02$1.04ViewN/AView Earnings Details
1/27/2011Q4 2010$0.67$0.68ViewN/AView Earnings Details
10/27/2010Q3 2010$0.76$0.54ViewN/AView Earnings Details
7/30/2010Q2 2010$0.80$0.73ViewN/AView Earnings Details
4/29/2010Q1 2010$0.86$1.02ViewN/AView Earnings Details
10/29/2009Q3 2009$0.68$0.73ViewN/AView Earnings Details
7/30/2009Q2 2009$0.68$0.82ViewN/AView Earnings Details
1/29/2009Q4 2008$0.59$0.63ViewN/AView Earnings Details
4/24/2008Q1 2008$0.60$0.52ViewN/AView Earnings Details
1/31/2008Q4 2007$0.50$0.52ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

AstraZeneca (NYSE:AZN) Dividend Information

AstraZeneca pays an annual dividend of $1.37 per share, with a dividend yield of 3.88%. AZN's most recent semiannual dividend payment was Monday, March 19. AstraZeneca pays out 32.01% of its earnings out as a dividend.
Most Recent Dividend:3/19/2018
Annual Dividend:$1.37
Dividend Yield:3.88%
Dividend Growth:-21.20% (3 Year Average)
Payout Ratio:32.01% (Trailing 12 Months of Earnings)
80.59% (Based on This Year's Estimates)
71.73% (Based on Next Year's Estimates)
Dividend Payments by Quarter for AstraZeneca (NYSE:AZN)

AstraZeneca (NYSE:AZN) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
2/5/2018semiannual$0.955.62%2/15/20182/16/20183/19/2018
7/28/2017None$0.442.98%8/9/20178/11/20179/11/2017
2/3/2017semiannual$0.956.81%2/15/20172/17/20173/20/2017
7/29/2016$0.448/10/20168/12/20169/12/2016
2/5/2016$0.932/17/20162/19/20163/21/2016
2/10/2015semiannual$1.905.57%2/18/20152/20/20153/23/2015
8/1/2014semiannual$0.902.48%8/13/20148/15/20149/15/2014
2/10/2014special$1.902.79%2/19/20142/21/20143/24/2014
8/2/2013semiannual$0.903.52%8/14/20138/16/20139/16/2013
2/1/2013special$1.903.72%2/13/20132/15/20133/18/2013
(Data available from 1/1/2013 forward)

Insider Trades

AstraZeneca (NYSE AZN) Insider Trading and Institutional Ownership History

Institutional Ownership Percentage: 15.14%
Insider Trading History for AstraZeneca (NYSE:AZN)
Institutional Ownership by Quarter for AstraZeneca (NYSE:AZN)

AstraZeneca (NYSE AZN) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
(Data available from 1/1/2013 forward)

Headlines

AstraZeneca (NYSE AZN) News Headlines

Source:
DateHeadline
3 Things In Biotech, April 20: AstraZeneca Re-Enters The Big Leagues, Aduro Looks Ahead, Lilly Looks Close3 Things In Biotech, April 20: AstraZeneca Re-Enters The Big Leagues, Aduro Looks Ahead, Lilly Looks Close
seekingalpha.com - April 21 at 8:16 AM
AstraZeneca (AZN) Downgraded by BidaskClub to HoldAstraZeneca (AZN) Downgraded by BidaskClub to Hold
www.americanbankingnews.com - April 19 at 1:56 PM
BRIEF-Astrazeneca says US FDA Approves Tagrisso As 1st-Line Treatment For EGFR-Mutated Non-Small Cell Lung ...BRIEF-Astrazeneca says US FDA Approves Tagrisso As 1st-Line Treatment For EGFR-Mutated Non-Small Cell Lung ...
www.reuters.com - April 19 at 8:12 AM
AstraZeneca cancer drug Tagrisso gets FDA approvalAstraZeneca cancer drug Tagrisso gets FDA approval
www.marketwatch.com - April 19 at 8:12 AM
AstraZeneca wins US approval for 1st-line use of lung cancer drugAstraZeneca wins US approval for 1st-line use of lung cancer drug
www.reuters.com - April 19 at 8:12 AM
AstraZeneca wins U.S. approval for 1st-line use of lung cancer drugAstraZeneca wins U.S. approval for 1st-line use of lung cancer drug
finance.yahoo.com - April 19 at 8:12 AM
US FDA Approves TAGRISSO® (osimertinib) As 1st-Line Treatment For EGFR-Mutated Non-Small Cell Lung CancerUS FDA Approves TAGRISSO® (osimertinib) As 1st-Line Treatment For EGFR-Mutated Non-Small Cell Lung Cancer
www.prnewswire.com - April 18 at 7:46 PM
A new Highmark contract with a pharma company part of a growing trend in drug purchasingA new Highmark contract with a pharma company part of a growing trend in drug purchasing
finance.yahoo.com - April 17 at 6:00 PM
BRIEF-Highmark Inc Signs Outcomes-Based Agreement With Astrazeneca For SymbicortBRIEF-Highmark Inc Signs Outcomes-Based Agreement With Astrazeneca For Symbicort
www.reuters.com - April 17 at 8:24 AM
Highmark Inc. Signs Outcomes-Based Agreement with AstraZeneca for SymbicortHighmark Inc. Signs Outcomes-Based Agreement with AstraZeneca for Symbicort
www.prnewswire.com - April 17 at 8:24 AM
An Intrinsic Calculation For AstraZeneca PLC (LON:AZN) Shows It’s 34% UndervaluedAn Intrinsic Calculation For AstraZeneca PLC (LON:AZN) Shows It’s 34% Undervalued
finance.yahoo.com - April 17 at 8:24 AM
AstraZeneca (AZN) Lowered to "Sell" at BidaskClubAstraZeneca (AZN) Lowered to "Sell" at BidaskClub
www.americanbankingnews.com - April 16 at 9:16 PM
How Will This Unexpected War For First-Line Lung End?How Will This Unexpected War For First-Line Lung End?
seekingalpha.com - April 16 at 8:12 AM
BRIEF-AstraZeneca says Updated Overall Survival Data For Lynparza(Olaparib) In Gbrca-Mutated Her2-Negative ...BRIEF-AstraZeneca says Updated Overall Survival Data For Lynparza(Olaparib) In Gbrca-Mutated Her2-Negative ...
www.reuters.com - April 16 at 8:12 AM
BRIEF-AstraZeneca Updates On Overall Survival Data For Lynparza Presented At AACRBRIEF-AstraZeneca Updates On Overall Survival Data For Lynparza Presented At AACR
www.reuters.com - April 16 at 8:12 AM
Jefferies Group Weighs in on AstraZenecas FY2018 Earnings (AZN)Jefferies Group Weighs in on AstraZeneca's FY2018 Earnings (AZN)
www.americanbankingnews.com - April 16 at 2:31 AM
AstraZeneca (AZN) Rating Reiterated by CowenAstraZeneca (AZN) Rating Reiterated by Cowen
www.americanbankingnews.com - April 15 at 9:31 AM
BRIEF-Molecular Partners To Cooperate With Astrazeneca On Ongoing Oncology Clinical StudyBRIEF-Molecular Partners To Cooperate With Astrazeneca On Ongoing Oncology Clinical Study
www.reuters.com - April 13 at 8:16 AM
Form 6-K ASTRAZENECA PLC For: Apr 13Form 6-K ASTRAZENECA PLC For: Apr 13
www.streetinsider.com - April 13 at 8:16 AM
Talend Connect 2018: New Speakers Include AstraZeneca, Royal Caribbean & TD BankTalend Connect 2018: New Speakers Include AstraZeneca, Royal Caribbean & TD Bank
www.globenewswire.com - April 12 at 8:26 AM
AstraZeneca (AZN) Rating Reiterated by Piper JaffrayAstraZeneca (AZN) Rating Reiterated by Piper Jaffray
www.americanbankingnews.com - April 11 at 7:53 PM
How AstraZeneca’s 1Q18 Shook OutHow AstraZeneca’s 1Q18 Shook Out
finance.yahoo.com - April 10 at 8:20 AM
Zacks Investment Research Downgrades AstraZeneca (AZN) to SellZacks Investment Research Downgrades AstraZeneca (AZN) to Sell
www.americanbankingnews.com - April 9 at 11:02 AM
Ionis and AstraZeneca Advance New Drug for NASHIonis and AstraZeneca Advance New Drug for NASH
www.prnewswire.com - April 9 at 8:14 AM
AstraZeneca (AZN) Upgraded to "Outperform" at Credit Suisse GroupAstraZeneca (AZN) Upgraded to "Outperform" at Credit Suisse Group
www.americanbankingnews.com - April 7 at 12:26 PM
Cowen Reiterates Hold Rating for AstraZeneca (AZN)Cowen Reiterates Hold Rating for AstraZeneca (AZN)
www.americanbankingnews.com - April 7 at 12:03 AM
Zacks: Analysts Anticipate AstraZeneca plc (AZN) to Post $0.46 Earnings Per ShareZacks: Analysts Anticipate AstraZeneca plc (AZN) to Post $0.46 Earnings Per Share
www.americanbankingnews.com - April 6 at 10:09 AM
Form 6-K ASTRAZENECA PLC For: Apr 05Form 6-K ASTRAZENECA PLC For: Apr 05
www.streetinsider.com - April 5 at 10:05 AM
AstraZeneca plc (AZN) Given Consensus Recommendation of "Hold" by BrokeragesAstraZeneca plc (AZN) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - April 4 at 5:39 PM
PRESS DIGEST- Financial Times - April 4PRESS DIGEST- Financial Times - April 4
finance.yahoo.com - April 4 at 8:16 AM
FDA accepts AstraZenecas application for moxetumomab pasudotoxFDA accepts AstraZeneca's application for moxetumomab pasudotox
seekingalpha.com - April 3 at 8:17 AM
AstraZeneca: FDA Grants Moxetumomab Pasudotox BLA Priority ReviewAstraZeneca: FDA Grants Moxetumomab Pasudotox BLA Priority Review
www.nasdaq.com - April 3 at 8:17 AM
AstraZeneca: FDA Approves BYDUREON For Expanded Use - Quick FactsAstraZeneca: FDA Approves BYDUREON For Expanded Use - Quick Facts
www.nasdaq.com - April 3 at 8:17 AM
AstraZeneca, Merck: European Medicines Agency To Review MAA For LynparzaAstraZeneca, Merck: European Medicines Agency To Review MAA For Lynparza
www.nasdaq.com - April 3 at 8:17 AM
AstraZeneca cancer drugs cross EU, US hurdlesAstraZeneca cancer drugs cross EU, US hurdles
www.marketwatch.com - April 3 at 8:17 AM
US FDA Accepts Biologics License Application for Moxetumomab Pasudotox in Hairy Cell LeukemiaUS FDA Accepts Biologics License Application for Moxetumomab Pasudotox in Hairy Cell Leukemia
finance.yahoo.com - April 3 at 8:17 AM
US FDA Approves BYDUREON for Use with Basal Insulin in Patients with Type 2 Diabetes with Inadequate Glycemic ControlUS FDA Approves BYDUREON for Use with Basal Insulin in Patients with Type 2 Diabetes with Inadequate Glycemic Control
finance.yahoo.com - April 3 at 8:17 AM
Compugen inks antibody development deal with AstraZeneca; shares ahead 11% premarketCompugen inks antibody development deal with AstraZeneca; shares ahead 11% premarket
seekingalpha.com - April 2 at 8:33 AM
Compugen, AstraZeneca unit in cancer drug development dealCompugen, AstraZeneca unit in cancer drug development deal
finance.yahoo.com - April 2 at 8:33 AM
AstraZeneca (AZN) Downgraded by Zacks Investment Research to "Sell"AstraZeneca (AZN) Downgraded by Zacks Investment Research to "Sell"
www.americanbankingnews.com - March 30 at 11:10 PM
AstraZeneca (AZN) Stock Rating Upgraded by Zacks Investment ResearchAstraZeneca (AZN) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - March 29 at 12:44 PM
AstraZenecas Symbicort ([budesonide + formoterol]) Drug Analysis Report 2018 - ResearchAndMarkets.comAstraZeneca's Symbicort ([budesonide + formoterol]) Drug Analysis Report 2018 - ResearchAndMarkets.com
www.businesswire.com - March 29 at 8:21 AM
AstraZeneca (AZN) Given a $38.00 Price Target at BMO Capital MarketsAstraZeneca (AZN) Given a $38.00 Price Target at BMO Capital Markets
www.americanbankingnews.com - March 28 at 8:42 PM
ValuEngine Downgrades AstraZeneca (AZN) to BuyValuEngine Downgrades AstraZeneca (AZN) to Buy
www.americanbankingnews.com - March 24 at 1:56 PM
AstraZeneca (AZN) PT Set at $40.00 by BMO Capital MarketsAstraZeneca (AZN) PT Set at $40.00 by BMO Capital Markets
www.americanbankingnews.com - March 22 at 3:18 PM
AstraZeneca (AZN) Rating Increased to Strong-Buy at ValuEngineAstraZeneca (AZN) Rating Increased to Strong-Buy at ValuEngine
www.americanbankingnews.com - March 19 at 11:48 PM
AstraZeneca (AZN) Stock Rating Upgraded by Jefferies GroupAstraZeneca (AZN) Stock Rating Upgraded by Jefferies Group
www.americanbankingnews.com - March 19 at 5:34 PM
How AstraZeneca’s Oncology Products Performed in 4Q17How AstraZeneca’s Oncology Products Performed in 4Q17
finance.yahoo.com - March 13 at 8:19 AM
AstraZeneca: Phase 3 Imfinzi trial results delayedAstraZeneca: Phase 3 Imfinzi trial results delayed
www.marketwatch.com - March 12 at 8:42 AM
AstraZeneca sees pivotal lung cancer trial results later in 2018AstraZeneca sees pivotal lung cancer trial results later in 2018
finance.yahoo.com - March 12 at 8:42 AM

SEC Filings

AstraZeneca (NYSE:AZN) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

AstraZeneca (NYSE:AZN) Income Statement, Balance Sheet and Cash Flow Statement

Chart

AstraZeneca (NYSE AZN) Stock Chart for Saturday, April, 21, 2018

Loading chart…

This page was last updated on 4/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.